Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Janux Therapeutics Inc (JANX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: JANX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $84.12
1 Year Target Price $84.12
| 11 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 130.9% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.52B USD | Price to earnings Ratio - | 1Y Target Price 84.12 |
Price to earnings Ratio - | 1Y Target Price 84.12 | ||
Volume (30-day avg) 13 | Beta 2.96 | 52 Weeks Range 22.48 - 71.71 | Updated Date 07/11/2025 |
52 Weeks Range 22.48 - 71.71 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.36 |
Earnings Date
Report Date 2025-06-26 | When After Market | Estimate -0.3917 | Actual -0.38 |
Profitability
Profit Margin - | Operating Margin (TTM) -1216.61% |
Management Effectiveness
Return on Assets (TTM) -8.16% | Return on Equity (TTM) -9.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 516840751 | Price to Sales(TTM) 163.09 |
Enterprise Value 516840751 | Price to Sales(TTM) 163.09 | ||
Enterprise Value to Revenue 55.36 | Enterprise Value to EBITDA -33.8 | Shares Outstanding 59175200 | Shares Floating 37063768 |
Shares Outstanding 59175200 | Shares Floating 37063768 | ||
Percent Insiders 6.69 | Percent Institutions 117.03 |
Upturn AI SWOT
Janux Therapeutics Inc
Company Overview
History and Background
Janux Therapeutics is a biopharmaceutical company focused on developing innovative immunotherapies to treat cancer. It was founded in 2017 and is headquartered in San Diego, California. Janux's technology centers on TRACTr (T-cell Activating Redirected Checkpoint Technology) platform designed to enhance T-cell activity in the tumor microenvironment.
Core Business Areas
- TRACTr Platform Development: Development of TRACTr platform technology for creating tumor-targeted immunotherapies.
- Oncology Drug Development: Research and development of novel cancer therapeutics based on the TRACTr platform, including pipeline candidates targeting various tumor types.
Leadership and Structure
David M. Grayzel serves as the President and CEO. The company has a board of directors overseeing strategic direction. The organizational structure includes research, development, clinical, and administrative teams.
Top Products and Market Share
Key Offerings
- JANX007: Janux's lead product candidate targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. Currently in Phase 1 clinical trials. Competitive landscape includes radioligand therapies (e.g., Pluvicto by Novartis) and other immunotherapies.
- JANX008: A TRACTr product candidate targeting EGFR, currently in preclinical development. Competitors include EGFR-targeted therapies from companies such as AstraZeneca and Amgen.
- JANX009: A TRACTr product candidate targeting Claudin 6 (CLDN6), currently in preclinical development. Competitors include CLDN6-targeted therapies from companies such as BioNTech.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by the success of checkpoint inhibitors and other novel therapeutic approaches. The demand for targeted and effective cancer treatments is a major market driver.
Positioning
Janux Therapeutics is positioned as an innovator in the immunotherapy space, utilizing its TRACTr platform to develop targeted T-cell engagers. Its competitive advantage lies in its ability to potentially minimize off-target toxicity and enhance efficacy.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is estimated to reach hundreds of billions of dollars. Janux's positioning with TRACTr and its multiple candidates will give it a chance to grow within this market
Upturn SWOT Analysis
Strengths
- Novel TRACTr platform technology
- Strong intellectual property portfolio
- Experienced management team
- Promising preclinical and early clinical data
Weaknesses
- Early-stage clinical development (high risk)
- Reliance on a single technology platform
- Limited financial resources compared to larger pharmaceutical companies
- High attrition rate in drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of TRACTr platform to additional cancer targets
- Positive clinical trial results leading to regulatory approvals
- Increasing demand for targeted cancer therapies
Threats
- Clinical trial failures
- Competition from established immunotherapy companies
- Regulatory hurdles
- Patent disputes
Competitors and Market Share
Key Competitors
- NVS
- AZN
- AMGN
- BNTX
Competitive Landscape
Janux is a relatively small player compared to established pharmaceutical companies like Novartis, AstraZeneca, Amgen and BioNTech. Its competitive advantage lies in its novel TRACTr platform, but it faces challenges in terms of resources and clinical development risk.
Growth Trajectory and Initiatives
Historical Growth: Historical growth primarily consists of advancing pipeline candidates through preclinical and early clinical development.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and potential partnerships. Analyst estimates vary and are subject to change.
Recent Initiatives: Recent initiatives include advancing JANX007 into later-stage clinical trials and expanding the TRACTr platform to additional cancer targets.
Summary
Janux Therapeutics is an early-stage biotech company with a promising TRACTr platform. The company's success hinges on positive clinical trial results and strategic partnerships. While its technology is innovative, it faces significant risks associated with drug development and competition from larger players. Janux needs to carefully manage its cash burn and execute on its clinical development plans to realize its full potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Janux Therapeutics Investor Relations
- SEC Filings
- Company Press Releases
- Analyst Reports (FactSet, Bloomberg)
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Janux Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-06-11 | President, CEO & Director Dr. David Alan Campbell Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 91 | Website https://www.januxrx.com |
Full time employees 91 | Website https://www.januxrx.com | ||
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.